Michael Drucker, MD
Clinical Cardiac Electrophysiology · Winston Salem, NCNPI 1780664128
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. ZOLL Respicardia, Inc. accounts for 62.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $7,297 and has fallen 63.8% since, to $2,645 in 2025.
Across 578 payments — averaging $63.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$23K
- Abbott$3K
- Medtronic$3K
- Boston Scientific$2K
- Novartis$1K
- Cardiva Medical, Inc.$652
- plus $4K from 19 others
Across 478 payments — averaging $538.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Respicardia, Inc.$166K
- Biotronik Inc.$77K
- Boston Scientific$14K
What the payments were for
- Consulting fees$7802%
- Speaking & faculty fees$20,00054%
- Travel & lodging$5,06814%
- Food & beverage$10,99330%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 17 | $22,970 |
| Abbott | 52 | $3,380 |
| Medtronic(2 entities) | 63 | $2,537 |
| Boston Scientific | 119 | $2,063 |
| Novartis | 57 | $1,002 |
| Cardiva Medical, Inc. | 41 | $652 |
| Biotronik Inc. | 27 | $584 |
| AstraZeneca | 33 | $574 |
| E.r. Squibb & Sons, L.L.C. | 40 | $456 |
| Johnson & Johnson | 29 | $412 |
| Amgen | 20 | $409 |
| Biosense Webster, Inc. | 15 | $385 |
| Boehringer Ingelheim | 18 | $337 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $326 |
| Cvrx, Inc. | 3 | $200 |
| Atricure, Inc. | 4 | $140 |
| Philips North America LLC | 3 | $133 |
| Pfizer | 5 | $88 |
| Elutia, Inc. | 3 | $77 |
| Bayer | 2 | $35 |
| Novo Nordisk | 2 | $34 |
| Vital Connect, Inc | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Convatec Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$22,658
- AVEIR$1,544
- Ensite Cardiac Mapping System$780
- Micra$703
- Azure$146
- Barostim Neo System$127
- Watchman$123
How this compares
$36,874 in reported general payments places this provider in the 60th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.
See all clinical cardiac electrophysiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 451 | $496,930 |
| XareltoRivaroxaban | 123 | $128,195 |
| MultaqDronedarone Hcl | 63 | $72,011 |
| EntrestoSacubitril/Valsartan | 13 | $23,675 |
| Dofetilide | 40 | $15,088 |
| Metoprolol Succinate | 367 | $6,813 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 172 | $3,933 |
| SotalolSotalol Hcl | 151 | $3,907 |
| Flecainide Acetate | 59 | $2,266 |
| Digoxin | 88 | $1,305 |
| ClopidogrelClopidogrel Bisulfate | 152 | $953 |
| Carvedilol | 102 | $936 |
| Atorvastatin Calcium | 89 | $785 |
| Amiodarone Hcl | 63 | $676 |
| Furosemide | 91 | $528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $496,930451 claims |
| Johnson & JohnsonXarelto | $412 | $128,195123 claims |
| NovartisEntresto | $1,002 | $23,67513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.
Other clinical cardiac electrophysiology in Winston Salem
- Lai Chow KokWinston Salem$74K
- Natalie BradfordWinston Salem$57K
- George WaitsWinston Salem$55K
- Prashant BhaveWinston Salem$47K
- Kashif ChaudhryWinston Salem$19K
- Rafael CavalcantiWinston Salem$19K
- Takeki SuzukiWinston Salem$16K
- Nicholas CostaWinston Salem$15K
- Mark MitchellWinston Salem$15K
- Michael ManogueAsheville$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.